• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Lay Offs coming soon

Quote








Considering we have restructured or reorganized to best meet the needs of our markets and customers (lay offs) 4 of the last 5 years, the odds of another in Q4 of this year are good. We displaced nearly 400 people last year when we exceeded most projections, especially with Ozempic. Slow/no Rybelsus makes it almost a certainty it’s happening again.
 












anonymous said:
FYI Layoffs Will be inevitable! Rybelsus is underperforming and look for more layoffs coming as early as September and especially last quarter of the year!
Click to expand...

Unfortunately, this is true. However, it has nothing to do with Rybelsus. It’s always been part of the plan. Ultimate goal is a singular sales force (no specialty) with 820 HCS (Health Care Specialist). We’ll be there by 2025 at the latest. You heard it here first.
 




anonymous said:
Unfortunately, this is true. However, it has nothing to do with Rybelsus. It’s always been part of the plan. Ultimate goal is a singular sales force (no specialty) with 820 HCS (Health Care Specialist). We’ll be there by 2025 at the latest. You heard it here first.
Click to expand...

Funny thing; I started with Novo 20 years ago when the number of reps was just a few hundred. Unnecessary expansion after unnecessary expansion got Novo to where it is today. Until Victoza, we sold ONLY insulin. Mix, short acting, long acting; all insulin. The headcount on the 2005 QE 2 trip was approximately 900 +/-. Looks like that’s where they are headed. What’s old is new again.
 




It is that time of year. I am sure we will
Keep laying off that is the way Novo rolls these days. They shouldn’t keep rehiring for all the positions that have been vacant. But the DBM are to worried about losing there job. So guess what they keep hiring . Why don’t we put a hiring freeze in place oh wait we already are where we want to be and we have already trimmed the fat that was last years line but wait now it’s the same time of year what will they say recent headwinds in the Buisness I am sure it will be some line that we think we won’t understand. Listen up people who may being lured to come over to fill these vacancy please spare yourself and stay where you are this company is a huge flight risk at this point with one molecule yes one molecule.
 








We could lay off have the managers
All of obesity educators
Most of the directors, and business would function fine every day. We would not miss a beat.
Instead it will be the reps who go first.
 








anonymous said:
It is that time of year. I am sure we will
Keep laying off that is the way Novo rolls these days. They shouldn’t keep rehiring for all the positions that have been vacant. But the DBM are to worried about losing there job. So guess what they keep hiring . Why don’t we put a hiring freeze in place oh wait we already are where we want to be and we have already trimmed the fat that was last years line but wait now it’s the same time of year what will they say recent headwinds in the Buisness I am sure it will be some line that we think we won’t understand. Listen up people who may being lured to come over to fill these vacancy please spare yourself and stay where you are this company is a huge flight risk at this point with one molecule yes one molecule.
Click to expand...

Hopefully this was written after 15 beers.
 












This is true. The Company has to prepare for the financial hardship of Victoza going generic soon. Also, Lilly coming out with GLP will take major marketshare from overall market. Another round of layoffs have been in the plan for a while.
 




Hate to agree with you and can't believe we are talking about this again, but generic Victoza will hurt as will the combo agonist if it is approved. One of the regional directors stated, when referring to that product, that it will be a 'major market event'.
 




We are the layoff queen!!!! No transparency ever and we keep laying off. So let’s all stay here and say oh it won’t happen to me well it will at some point our number is up. Plus we have lots of reps in .that 50-60 age range they need to weed out before they pay up the bennies. That is why we have unlimited vacation now and also they moved our bonus for q2 until September I bet not everyone got wind of that . Then they will pay q3 in December along with our severance package. Can’t we have one normal work year where we don’t have to worry about our job. For the love of god this is to much anymore!!!!
 




anonymous said:
Hate to agree with you and can't believe we are talking about this again, but generic Victoza will hurt as will the combo agonist if it is approved. One of the regional directors stated, when referring to that product, that it will be a 'major market event'.
Click to expand...

Generic Victoza won't come to the market till holidays 2023. Company will be pushing hard in 2022 and 2023 to switch everyone to O and R. Not a reason for layoffs.
Tirzepatide has nice data but look how long it takes to convince these dumb docs about GLP1. They won't get gip. Cardiologists won't care for it no CV. We got sema 2 dose coming prob before Lilly drug gets approved.
But Lilly will rebate and contract circles around us so it'll make it on every formulary.

Prob not layoffs but "restructuring" everyone to obesity. Rybelsus ship has sunk for now.
 








anonymous said:
Generic Victoza won't come to the market till holidays 2023. Company will be pushing hard in 2022 and 2023 to switch everyone to O and R. Not a reason for layoffs.
Tirzepatide has nice data but look how long it takes to convince these dumb docs about GLP1. They won't get gip. Cardiologists won't care for it no CV. We got sema 2 dose coming prob before Lilly drug gets approved.
But Lilly will rebate and contract circles around us so it'll make it on every formulary.

Prob not layoffs but "restructuring" everyone to obesity. Rybelsus ship has sunk for now.
Click to expand...

Is there some FDA regulation that prohibits us from having one rep sell ozempic and wegovy? Or is Novo just being careful? It would just make sense to have one pod selling the whole portfolio, it's the same dang molecule.
 




Top Bottom
Back
Quote